Patents by Inventor Michael Ehrenstein

Michael Ehrenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the treatment of autoimmune diseases
    Patent number: 10376518
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 13, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20160030439
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 4, 2016
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • Method for Predicting the Response of a Patient to Treatment with an Anti-TNF Alpha Antibody
    Publication number: 20100196402
    Abstract: The present invention relates to a method for predicting the response of a patient to treatment with an anti-TNF? therapy, in particular an anti-TNF? antibody, the method comprising: (a) providing an in vitro sample of T cells from the patient; (b) exposing said T cells to an anti-TNF? therapy; and (c) determining whether regulatory T cells are induced in said sample of T cells wherein the induction of regulatory T cells indicates that the patient is likely to respond to treatment with said anti-TNF? therapy.
    Type: Application
    Filed: May 20, 2008
    Publication date: August 5, 2010
    Applicant: UCL BUSINES PLC
    Inventors: Michael Ehrenstein, Claudia Mauri